Archive

Tag: ACOEP 2017

The Critical Pulmonary Embolism Patient

Background: Previously, I had given a talk on the use of thrombolytics in submassive PE in 2016. This year, I had the privilege of speaking at ACOEP 2017 again with an update on the critical pulmonary embolism patient. This post …

Read More
Thoracic and Respiratory

The Death of MONA in ACS: Part IV – Aspirin

Background: Aspirin is the most widely used antiplatelet agent in acute coronary syndromes.  The bulk of the evidence for this came from the second international study of infarct survival (ISIS-2) published in the Lancet in 1988.

Read More
Cardiovascular

The Death of MONA in ACS: Part III – Nitroglycerin

Background: Nitroglycerin is a first line agent in the treatment of ACS. The physiologic basis for it’s use rests on it’s ability to promote coronary vasodilation resulting in increased blood flow to the coronary arteries . Nitroglycerin, is typically given …

Read More
Cardiovascular

The Death of MONA in ACS: Part II – Oxygen

Background: The first report for supplemental oxygen for angina was in 1900, and since then oxygen therapy has been a commonly used treatment of patients with ST-Elevation Myocardial Infarction (STEMI).  The reason for this is the belief that supplemental oxygen …

Read More
Cardiovascular

The Death of MONA in ACS: Part I – Morphine

Background: Morphine is a commonly used medication in acute coronary syndromes (ACS) to help relieve pain which in turn can help reduce sympathetic tone.  Over the past few years however, there has been some concern raised about the drug-drug interactions …

Read More
Cardiovascular

Sponsored

0